Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$21.15
--
Market closed
$21.15
--
Day’s Range― - ―
52-Week Range$14.19 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.06M
Market Cap
$4.39B
Enterprise Value$4.66K
Total Cash (Recent Filing)$823.46M
Total Debt (Recent Filing)$430.96M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding282,680,700
10 Day Avg. Volume3,402,494
30 Day Avg. Volume3,055,098
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$26.91Price Target Upside27.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.13
Revenue Forecast (FY)$1.00B
Bulls Say, Bears Say
Bulls Say
Strong Revenue, ASP And Margin ExpansionSustained multi-factor commercial strength — sharp revenue growth, meaningful ASP increases and a structurally higher gross margin — indicates improving unit economics and pricing power in core molecular profiling. These shifts support durable operating leverage and long‑term margin sustainability if volumes persist.
Improving Cash Generation And LiquidityA transition to consistent positive operating and free cash flow versus prior years materially enhances financial flexibility. Strong cash generation supports continued investments, R&D, and commercialization while reducing near‑term refinancing risk, making the business less vulnerable to funding shocks over months.
Large Clinicogenomic Dataset And Expanding Commercial FootprintA proprietary, growing dataset and broad clinician adoption create durable competitive advantages for biomarker discovery, product development, and pharma partnerships. Combined with new test launches and EMR integration scale, this entrenches Caris in clinical workflows and enhances long‑term revenue diversification.
Bears Say
Persistent Net Losses And Negative MarginsDespite operating momentum, the company remains economically loss‑making at the net level with historically large net losses. Structural profitability risk persists until sustained positive net income and consistent coverage of non‑cash charges are achieved, limiting confidence in long‑term returns.
Volatile Balance Sheet HistoryMaterial swings in reported equity and periodic negative‑equity episodes signal past financing stress and make trend analysis unreliable. This volatility raises concern about potential future capital needs and the predictability of balance‑sheet strength over the medium term.
Reimbursement And Market Coding RiskDiagnostic pricing and reimbursement are structural drivers of long‑term revenue per test. Continued regulatory or payer pressure, coding changes, or adverse PAMA outcomes could materially compress ASPs and margins, making revenue durability contingent on reimbursement stability.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $4.39B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.024 by $0.024.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.01.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,680,700 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, beating expectations of -$0.024. Following the earnings report the stock price went down -18.599%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.91 (27.23% Upside)
$26.91 (27.23% Upside)
Blogger Sentiment
Bullish
CAI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 349.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $501.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
298.65%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Stock 12 Month Forecast
Average Price Target
$26.91
▲(27.23% Upside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
48.82% Insiders
16.19% Mutual Funds
0.06% Other Institutional Investors
28.83% Public Companies and
Individual Investors